Methotrexate as a steroid‐sparing agent in coganapos;s syndrome: comment on the concise communication by richardson

Pouchot, J.; Vinceneux, P; Bouccara, D.; Sterkers, Olivier; Bodelet, Bernard

doi:10.1002/art.1780380936

Cited by 16 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For patients requiring high and prolonged doses, additional immunosuppression is appropriate. Methotrexate is the first-line steroid sparing agent [26, 27]. However, patients without systemic disease or severe eye disease unmanageable by topical corticosteroids should not be subjected to protracted courses of corticosteroids or immunosuppressive agents, particularly when little gain in hearing is obtained with their use [19].…”

Section: Discussionmentioning

confidence: 99%

Interstitial Keratitis, Vertigo, and Vasculitis: Typical Cogan’s Syndrome

Ahad

Maleki

Hormozi

et al. 2014

Case Reports in Medicine

View full text Add to dashboard Cite

Cogan's syndrome (CS) is a chronic inflammatory disorder of unknown etiology that most commonly affects young adults. Clinical hallmarks are bilateral interstitial keratitis and vestibuloauditory dysfunction. Association between CS and systemic vasculitis as well as aortitis also exists. The diagnosis of CS is based upon presence of characteristic inflammatory eye disease and vestibuloauditory dysfunction. We describe classic Cogan's syndrome in a 47-year-old female from Ardabil. The patient was admitted with headache, vertigo, nausea, vomiting, right leg claudication, musculoskeletal pains, bilateral hearing loss, and blindness for the past two months. Ophthalmologic examination revealed that visual acuity was 0.1 bilaterally. Conjunctival hyperemia, bilateral cataract, and interstitial keratitis were detected with a slit lamp examination. Pure tone audiogram (PTA) and auditory brain stem response (ABR) showed bilateral sensorineural hearing loss. The other differential diagnosis of CS was studied and ruled out. Pulse i.v. methylprednisolone and cyclophosphamide were given and were followed by oral prednisolone and cyclophosphamide. Clinical follow-up showed partial improvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Interstitial Keratitis, Vertigo, and Vasculitis: Typical Cogan’s Syndrome

Ahad

Maleki

Hormozi

et al. 2014

Case Reports in Medicine

View full text Add to dashboard Cite

show abstract

“… 68 , 69 Thus, the efficacy and safety of MTX was assessed in several case series, case reports and one retrospective study, mainly during the maintenance phase. 12 , 32 , 44 , 51 , 61 , 64 , 70 , 71 The use of MTX was discussed as an option also for the treatment of CS in pediatric age. 72 , 73 Intolerance or poor effectiveness of this immunosuppressant in CD has been reported.…”

Section: Multidisciplinary Approach To Treatment Of Csmentioning

confidence: 99%

Optimal management of Cogan’s syndrome: a multidisciplinary approach

D’Aguanno¹,

Ralli²,

Vincentiis³

et al. 2017

JMDH

View full text Add to dashboard Cite

Cogan’s syndrome (CS) is a rare disorder characterized by nonsyphilitic interstitial keratitis (IK) and audio-vestibular symptoms. CS affects mainly young Caucasian adults, mostly during their first three decades of age, and may develop into typical and atypical variants. Typical CS manifests primarily with IK and hearing loss, whereas atypical CS usually presents with inflammatory ocular manifestations in association with audio-vestibular symptoms but mostly different Ménière-like symptoms and, more frequently, with systemic inflammation (70%), of which vasculitis is the pathogenic mechanism. CS is considered as an autoimmune- or immune-mediated disease supported mainly by the beneficial response to corticosteroids. Using well-developed assays, antibodies to inner ear antigens, anti-Hsp70, and antineutrophil cytoplasmic antibodies were found to be associated with CS. Corticosteroids represent the first line of treatment, and multiple immunosuppressive drugs have been tried with variable degrees of success. Tumor necrosis factor-alpha blockers and other biological agents are a recent novel therapeutic option in CS. Cochlear implantation is a valuable rescue surgical strategy in cases with severe sensorineural hearing loss unresponsive to intensive and/or innovative immunosuppressive regimens.

show abstract

“…При высокой активности СК и необходимости длительно-го назначения высоких доз ГК к терапии присоединяют цитостатики, в первую очередь МТ, который позволяет ре-дуцировать дозу ГК при отсутствии сообщений о неблаго-приятных реакциях [13,18,36,37]. Среди других цитоста-тиков, с переменным успехом используемых при СК, сле-дует отметить ЦФ, широко применяемый при воспали-тельной патологии глаз, азатиоприн, микофенолата мофе-тил, циклоспорин [10,13,15,[38][39][40].…”

Section: Cogan's Syndrome Is a New Nosological Entity In The Current unclassified

Cogan's syndrome is a new nosological entity in the current classification of systemic vasculitides: A clinical case and a review of literature

Бекетова¹

2016

rsp

View full text Add to dashboard Cite

Methotrexate as a steroid‐sparing agent in coganapos;s syndrome: comment on the concise communication by richardson

Cited by 16 publications

References 3 publications

Interstitial Keratitis, Vertigo, and Vasculitis: Typical Cogan’s Syndrome

Interstitial Keratitis, Vertigo, and Vasculitis: Typical Cogan’s Syndrome

Optimal management of Cogan’s syndrome: a multidisciplinary approach

Cogan's syndrome is a new nosological entity in the current classification of systemic vasculitides: A clinical case and a review of literature

Contact Info

Product

Resources

About

Methotrexate as a steroid‐sparing agent in coganapos;s syndrome: comment on the concise communication by richardson

Cited by 16 publications

References 3 publications

Interstitial Keratitis, Vertigo, and Vasculitis: Typical Cogan’s Syndrome

Interstitial Keratitis, Vertigo, and Vasculitis: Typical Cogan’s Syndrome

Optimal management of Cogan&rsquo;s syndrome: a multidisciplinary approach

Cogan's syndrome is a new nosological entity in the current classification of systemic vasculitides: A clinical case and a review of literature

Contact Info

Product

Resources

About

Optimal management of Cogan’s syndrome: a multidisciplinary approach